recombinant soluble human cd4
Recombinant proteinexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002005)
Timeline
Indications
Studied for
Mechanism of action
- Envelope glycoprotein gp160INHIBITOR
Q993A8 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant soluble human cd4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000659 | Phase 2 | Nov 2, 1999 | Biogen, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000721 | Phase 1 | Nov 2, 1999 | Biogen, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000984 | Phase 1 | Nov 2, 1999 | Genentech, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002004 | Phase 1 | Nov 2, 1999 | Genentech |
| NCT00002005 | N/A | Nov 2, 1999 | Genentech |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 3 | 2 | 2 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 2 | 1999 |
| Biogen | For profit | 2 | 0 | 2 | 1999 |
3 organizations
Page 1 / 1